文献速递中医内科中药与中成药合理使用

台湾肺癌患者中药使用特征及其对生存的影响

Characteristics of Chinese herbal medicine usage and its effect on survival of lung cancer patients in Taiwan.
PubMed 文献 · J Ethnopharmacol · 2017-10-31

该研究基于台湾6939例肺癌患者,匹配264例中药使用者和528例非使用者,分析中药使用模式与生存关系。结果显示中药组调整合并症后死亡风险比更低(0.48,95%CI[0.39-0.61],p<0.001),累积生存概率更高(p<0.0001),常用方剂包括补中益气汤、香砂六君子汤、百合固金汤,常用单药为贝母、杏仁、葛根。

要点

  • 中药作为辅助治疗可能降低肺癌患者死亡风险比(0.48,95%CI[0.39-0.61])。
  • 中药组累积生存概率高于非中药组(p<0.0001,log rank检验)。
  • 常用方剂为补中益气汤、香砂六君子汤、百合固金汤;常用单药为贝母、杏仁、葛根。

核心结论

  • 中药作为辅助治疗可能降低肺癌患者的死亡风险比。
  • 中药组累积生存概率高于非中药组。

研究设计与样本

  • 研究识别6939例肺癌患者(ICD-9-CM: 162),匹配264例中药使用者与528例非使用者,匹配因素包括年龄、性别、病程和规律治疗。
  • 采用卡方检验、条件多因素逻辑回归、Kaplan-Meier法和log-rank检验进行分析。

主要发现

  • 中药组随访时间更长,高脂血症和肝硬化病例更多。
  • 调整合并症后,中药组死亡风险比为0.48(95%CI[0.39-0.61],p<0.001)。
  • 中药组累积生存概率高于非中药组(p<0.0001,log rank检验)。
  • 常用方剂前三为补中益气汤(BZYQT)、香砂六君子汤(XSLJZT)、百合固金汤(BHGJT);常用单药前三为贝母(BM)、杏仁(XR)、葛根(GG)。
  • 网络分析显示贝母为核心中药,桔梗(JG)和麦门冬汤(MMDT)为重要中药。

关键数值与推荐

  • 中药组死亡风险比0.48(95%CI[0.39-0.61],p<0.001),调整合并症后。
  • 累积生存概率比较p<0.0001(log rank检验)。

临床怎么用

  • 中药可作为肺癌辅助治疗选项,可能改善生存。
  • 常用方剂与单药可供临床参考,但需结合患者具体情况。

局限性

  • 研究为回顾性设计,可能存在选择偏倚和混杂因素。
  • 样本来自台湾地区,结论外推需谨慎。
  • 需要未来大规模随机临床试验验证中药的有效性、安全性和潜在相互作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: In Taiwan, lung cancer remains one of the deadliest cancers. Survival of lung cancer patients remains low, ranging from 6% to 18%. Studies have shown that Chinese herbal medicine (CHM) can be used to induce cell apoptosis and exhibit anti-inflammatoryanti-inflammatory activities in cancer cells. AIM OF THE STUDY: This study aimed to investigate the frequencies and patterns of CHM treatment for lung cancer patients and the effect of CHM on their survival probability in Taiwan. MATERIALS AND METHODS: We identified 6939 lung cancer patients (ICD-9-CM: 162). We allocated 264 CHM users and 528 CHM-non users, matched for age, gender, duration, and regular treatment. Chi-square test, conditional multivariable logistic regression, Kaplan-Meier method, and the log-rank test were used in this study. RESULTS: The CHM group was characterized by a longer follow up time and more cases of hyperlipidemia and liver cirrhosis. This group exhibited a lower mortality hazard ratio (0.48, 95% confidence interval [0.39-0.61], p < 0.001), after adjusting for comorbidities. The trend was also observed that the cumulative survival probability was higher in CHM than in non-CHM users (p < 0.0001, log rank test). Analysis of their CHM prescription pattern revealed that Bu-Zhong-Yi-Qi-Tang (BZYQT), Xiang-Sha-Liu-Jun-Zi-Tang (XSLJZT), and Bai-He-Gu-Jin-Tang (BHGJT); and Bei-Mu (BM), Xing-Ren (XR) and Ge-Gen (GG) were found to be the top three formulas and herbs, respectively. Among them, BM was the core CHM of the major cluster, and Jie-Geng (JG) and Mai-Men-Dong-Tang (MMDT) were important CHMs by CHM network analysis. CONCLUSION: The use of CHM as an adjunctive therapy may reduce the mortality hazard ratio of lung cancer patients. The investigation of their comprehensive CHM prescription patterns might be useful in future large-scale, randomized clinical investigations of agent effectiveness, safety, and potential interactions with conventional treatments for lung cancer patients.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Li TM, Yu YH, Tsai FJ, et al. Characteristics of Chinese herbal medicine usage and its effect on survival of lung cancer patients in Taiwan. J Ethnopharmacol. 2017. PMID: 29100936. doi:10.1016/j.jep.2017.10.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。